All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
How could new treatment options improve outcomes in FLT3-mutated AML?
Featured
Bookmark this article
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment options improve outcomes in FLT3-mutated acute myeloid leukemia (AML)?
How could new treatment options improve outcomes in FLT3-mutated AML?
Daver begins by outlining the nature of FLT3 mutations in patients with AML, including their association with a higher-risk prognosis, before discussing first- and second-generation FLT3 inhibitors and the studies that explored these. Daver goes on to outline a study on a venetoclax + gilteritinib combination in relapsed/refractory FLT3-mutated AML and its promising efficacy. Finally, Daver discusses studies aiming to improve outcomes for different patient groups, utilizing varying dosages and therapeutic combinations.
Your opinion matters
7 votes - 16 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox